SIBN SI-BONE, Inc.
USHealthcareAs of 2026-07-10 16:00
Why SIBN matters now
SI-BONE, Inc. (SIBN) is a US stock in Healthcare. The latest InvestLog snapshot shows $17.56 with +0.80% on the session and $778.8M in market capitalization; recent performance reads 1-month +6.74% and YTD -19.68%.
The latest financial table shown here is Q1 2026, with revenue of $52.6M, net income of $-4.3M, and EPS of $-0.10. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -0.8%.
The latest indexable market news headline is "SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $24.00; recent insider activity includes HILLEMAN JERYL L filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.89
P/S
3.41
EV/EBITDA
-112.92
DCF Value
$40.00
FCF Yield
-0.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
79.6%
Operating Margin
-9.7%
Net Margin
-8.1%
ROE
-9.6%
ROA
-6.9%
ROIC
-9.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $52.6M | $-4.3M | $-0.10 |
| Q4 2025 | $56.4M | $-1.6M | $-0.04 |
| FY 2025 | $200.9M | $-18.9M | $-0.44 |
| Q3 2025 | $48.7M | $-4.6M | $-0.11 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$24.00
Target (Median)
$24.00
Target Range
$24.00 - $24.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.70
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.